From Small Molecules to Biosimilars: Octet® BLI Transforming Analytical Assays
Venture into the realm of possibilities, where precision and innovation converge to redefine the future of research. The Octet® Biolayer Interferometry (BLI) platform continues to expand into novel applications while streamlining workflows. From detecting low analyte concentrations with enhanced sensitivity to revolutionizing small molecule and biosimilar analysis, explore the transformative power of Octet® BLI. Experience how enhanced sensitivity and rapid analysis are reshaping drug discovery, development, and bioprocessing. Whether you're delving into nanobody discovery or advancing diabetes research, Octet® BLI systems offer groundbreaking solutions that’ll elevate your scientific endeavors.
Unveiling Hidden Insights: Enhanced Analytics with New Heights of Sensitivity
Sensitivity is essential in kinetics, affinity, and quantitation assays, as it enables the precise detection of low analyte concentrations. This document presents compelling data demonstrating the Octet® R8e's capability to accurately detect analyte concentrations as low as 3.9 ng/mL (26 pM).
DownloadHow Low Can You Go? A New Era of Sensitivity in Octet® BLI
A comprehensive guide, showcasing best practices for generating high-quality data across a diverse array of compounds and molecular weights. By leveraging the capabilities of the Octet® R8e, researchers can enhance their experimental precision and efficiency, paving the way for groundbreaking discoveries.
DownloadComparability Study of GxP-Compliant Octet® R8 & Enhanced Octet® R8e Confirms Precision & Transferability
Regulatory reimagined: GxP-compliant Octet® R8 and enhanced R8e systems offer significant benefits for pharmaceutical and biological product regulatory applications. Key benefits: enhanced sensitivity- detect molecule >100 Da, high assay precision (CV <10%), seamless assay transferability, rapid processing, and successful drug approvals. Upgrade to Octet® R8e for confident discovery and development.
DownloadFrom Macro to Micro: A Leap in Small Molecule Sensitivity
Reshaping the analysis of small molecule inhibitors, the Octet® R8e targets sulfonamide interactions with Carbonic Anhydrase II, a key enzyme linked to diseases like glaucoma and cancer. The system's enhanced sensitivity and accuracy, provides reliable kinetic data comparable to traditional SPR methods, thus advancing drug development and lead optimization processes.
DownloadA Rapid and Automated Method for High-Throughput Nanobody Discovery
Transform nanobody discovery with the Octet® BLI platform, delivering rapid, automated high-throughput selection of target-specific binders with unparalleled efficiency. This innovative method streamlines phage display selection by immobilizing antigens on biosensors, reducing nonspecific binding and the number of panning rounds needed for high-affinity nanobody enrichment.
DownloadFcγ Receptor and Antigen Kinetic Screening for Rapid Biosimilar Downstream Processing Assessment
Octet® BL facilitates rapid kinetic screening of Fcγ Receptor and antigen interactions. It emphasizes generating high-quality kinetic data across drug development stages, enhancing throughput with a single analyte concentration. This approach bypasses traditional assays, aiding efficient biosimilar development by evaluating critical quality attributes (CQAs) and optimizing bioprocessing.
DownloadNovel Approach in Diabetes Research: Role of Biosensor Technology in Advancing GLP-1 Analog Development
Description: Exploring the cutting-edge use of Octet® Biolayer Interferometry (BLI) biosensor technology, it delves into revolutionizing GLP-1 analog development for diabetes treatment. It highlights GLP-1's role in glucose metabolism, insulin secretion, and its therapeutic potential in type 2 diabetes. The study examines the binding kinetics and affinity of GLP-1 analogs like Victoza®, Trulicity®, and Ozempic®, emphasizing the importance of structural modifications in drug development.
DownloadAAV Empty/Full Ratio Assessment Using the Octet® AAVX Biosensors
Tired of analyzing AAV empty/full capsid ratios the hard way? Try a novel, high-throughput method using Octet® AAVX biosensors. This approach analyzes intact viral capsids in crude and purified samples, accelerating workflows with precision and consistency. Perfect for screening in upstream and downstream bioprocessing stages of AAV development and manufacturing.
Download